A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
Keywords: Rigosertib; Myelodysplastic syndrome; Acute myeloid leukemia; Refractory; Cell cycle; Ras inhibitor;